^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    eftozanermin alfa (ABBV-621)

    i
    Company:
    AbbVie, Apogenix
    Drug class:
    TRAIL R2 agonist, TRAIL R1 agonist
    Related drugs:
    Apply
    A Study of the Safety and Tolerability of ABBV-621 in Participants With Previously-Treated Solid Tumors and Hematologic Malignancies (NCT03082209)
    Phase 1
    AbbVie
    Completed
    Last update posted :
    12/09/2022
    Initiation :
    03/20/2017
    Primary completion :
    01/21/2022
    Completion :
    01/21/2022
    KRAS
    |
    KRAS mutation • RAS mutation
    |
    Avastin (bevacizumab) • Venclexta (venetoclax) • 5-fluorouracil • irinotecan • leucovorin calcium • eftozanermin alfa (ABBV-621)